Mammen P. Mammen
Nessuna posizione attualmente
Profilo
Mammen P.
Mammen formerly worked at Vical, Inc., as Vice President-Clinical Vaccines from 2012 to 2017, Inovio Pharmaceuticals, Inc., as Senior Vice President-Clinical Development from 2020 to 2022, and Walter Reed Army Institute of Research, as Principal.
Dr. Mammen received his doctorate degree from The Pennsylvania State University and undergraduate degree from Williams College.
Precedenti posizioni note di Mammen P. Mammen
| Società | Posizione | Fine |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2022 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Formazione di Mammen P. Mammen
| The Pennsylvania State University | Doctorate Degree |
| Williams College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
| Walter Reed Army Institute of Research |
- Borsa valori
- Insiders
- Mammen P. Mammen
